- Advanced search
- Immuno Portal
- Malaria Portal
Ligand id: 7236
View more information in the IUPHAR Pharmacology Education Project: methylphenidate
Molecular properties generated using the CDK
|No information available.|
|Summary of Clinical Use|
|Used alongside educational and psychosocial intervention to treat attention deficit hyperactivity disorder (ADHD) and to treat narcolepsy.
An extended release, chewable formulation of methylphenidate hydrochloride (QuilliChew ER) was approved by the US FDA in December 2015. Cotempla XR-ODT, an extended-release orally disintegrating methylphenidate-containing tablet was FDA approved for ADHD in June 2017.
|Mechanism Of Action and Pharmacodynamic Effects|
|This drug blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, resulting in increased levels of monoamines active in the extraneuronal space. Neurotransmitter reuptake is performed by the transporter proteins SLC6A3 (dopamine) and SLC6A2 (norepinephrine). As these neurotransmitters are involved in maintaining alertness and sustaining thought and motivation this action may underlie the clinical benefits in ADHD. However the full molecular mechanism of action remains to be fully resolved. See the DrugBank link for further details.|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)